دورية أكاديمية
أعرض في EDS

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.

التفاصيل البيبلوغرافية
العنوان: Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.
المؤلفون: Arrieta, Javier, Moina, Iñigo, Molina, José, Gallardo, Isabel, Muñiz, María Luisa, Robledo, Carmen, García, Oscar, Vidaur, Fernando, Muñoz, Rosa Inés, Iribar, Izaskun, Aguirre, Román, Maza, Antonio
المصدر: International Journal of Nephrology & Renovascular Disease; 2014, Vol. 7, p353-359, 7p
مصطلحات موضوعية: CHRONIC kidney failure, DARBEPOETIN alfa, DRUG dosage, EPOETIN alfa (Drug), HEMODIALYSIS patients, HEMOGLOBIN synthesis, RETROSPECTIVE studies
مستخلص: Aim: The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. Methods: This was a multicenter, observational, retrospective study in patients aged ≥18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline. Results: We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months -12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P<0.0001), with an annual mean of 174.7 (88.7) international units (IU)/kg/week for epoetin versus 95.7 (43.4) (first year) and 91.4 (42.7) IU/kg/week (second year) for darbepoetin (65% and 64% reduction, respectively). The ESA resistance index decreased from 15.1 (8.5) IU/kg/week/g/dL with epoetin to 8.1 (3.9) (first year) and 7.9 (4.0) (second year) with darbepoetin (P<0.0001). The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. Conclusion: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Nephrology & Renovascular Disease is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا